Morphosys AG's net income is $-460M, below the Healthcare sector average of $16B.
Get informed when a big investor buys or sells
+ FollowAs of Mar 2024
Trailing 12 months ending Mar 2024
Loading...
Loading...
As of the most recent data (March 2024), MOR shows a net income of $-460M. That compares with $-72M in the prior-year period — down 536.3% year over year. That is below the Healthcare sector average of $16B. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, MOR's net income is now $-460M (was $-72M) — a 536.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Morphosys AG is outperforming or lagging.
The Healthcare sector average net income is about $16B. Morphosys AG is at $-460M, which is lower that average. That is roughly 102.8% below the sector mean. Use the comparison chart on this page to see how MOR stacks up against individual peers as well.
Tracking MOR's net income over time shows whether Morphosys AG is scaling, shrinking, or reshaping that part of the business. The current reading is $-460M That compares with $-72M in the prior-year period — down 536.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this net income page, Stockcircle has Morphosys AG's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net income (currently $-460M) with ownership activity and broader fundamentals.